Blood Coagulation

Walter H. Seegers; Gary L. Grammens; Lowell E. McCoy

doi:10.1055/s-0038-1654243

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1970; 24(03/04): 345-351
DOI: 10.1055/s-0038-1654243

Originalarbeiten – Original Articles – Travaux Originaux

Schattauer GmbH

Blood Coagulation

Role of Hageman Protein (F-XII) and Autoprothrombin II (F-IX?) in the Activation of Autoprothrombin III (F-X)^[*]

Walter H. Seegers

¹Department of Physiology and Pharmacology, Wayne State University, School of Medicine, Detroit, Michigan, U.S.A

,

Gary L. Grammens

¹Department of Physiology and Pharmacology, Wayne State University, School of Medicine, Detroit, Michigan, U.S.A

,

Lowell E. McCoy

¹Department of Physiology and Pharmacology, Wayne State University, School of Medicine, Detroit, Michigan, U.S.A

› Institutsangaben

Abstract

Summary

Preparations of platelet factor 3 accelerated the conversion of purified autoprothrombin III (F-X) to autoprothrombin C (F-X?). The reaction was slow and the yields were low. Purified Hageman factor or purified autoprothrombin II (F-IX?) functioned as platelet cofactors. Each increased the yield of autoprothrombin C from purified autoprothrombin III above that obtained with platelet factor 3 alone. Hageman protein thus has a role in the direct acceleration of the first basic reaction in blood coagulation. Purified prothrombin was made refractory to the two-stage analytical reagents with Hageman factor.

Volltext

Referenzen

References
1 Ratnoff O. D, Colopy J. E. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J. clin. Invest 34: 602 1955;
2 Ratnoff O. D, Margolius A. T. Hageman trait : Asymptomatic disorder of blood coagulation. Trans. Ass. Amer. Phycns 68: 149 1955;
3 Didisheim P. Purification of Hageman factor. Fed. Proc 20: 61 1961;
4 Haanen C, Hommes F, Berroad H, Morselt G. A case of Hageman factor deficiency and a method to purify the factor. Thrombos. Diathes. haemorrh. (Stuttg.) 05: 201 1960;
5 Ratnoff O. D, Davie E. W. The purification of activated Hageman factor (activated factor XII). Biochemistry 01: 967 1962;
6 Schoenmakers J. G. G, Kurstjens R. M, Haanen G, Zilliken F. Purification of activated Hageman factor. Thrombos. Diathes. haemorrh. (Stuttg.) 09: 546 1963;
7 Schoenmakers J. G. G, Matzke R, Haanen C, Zilliken F. Hageman factor, a novel sialoglycoprotein with esterase activity. Biochim. biophys. Acta (Amst.) 101: 166 1965;
8 Speer R. J, Ridgeway H, Hill M. J. Activated human Hageman factor (XII). Thrombos. Diathes. haemorrh. (Stuttg.) 14: 1 1965;
9 Grammens G. L. The isolation and properties of bovine Hageman factor (factor XII). M.S. Thesis, Wayne State Univ. Detroit; Michigan: 1966
10 Davie E. W, Ratnoff O. D. Waterfall sequence for intrinsic blood clotting. Science 145: 1310 1964;
11 Macfarlane R. G. An enzyme cascade in blood clotting mechanism, and its function as a biochemical amplifier. Nature (Lond.) 202: 498 1964;
12 Esnouf M. P. Biochemical aspects of blood coagulation. Proc. Roy. Soc. Ser. B 173: 269 1969;
13 Mammen E. F, Grammens G. L. The purification and some properties of bovine Hageman factor. Thrombos. Diathes. haemorrh. (Stuttg.) 18: 306 1967;
14 Glueck H. I, Roehll Jr. W. Myocardial infarction in a patient with a Hageman (factor XII) defect. Ann. intern. Med 64: 390 1966;
15 Hoak J. C, Swanson L. W, Warner E. D, Connor W. E. Myocardial infarction associated with severe factor XII deficiency. Lancet II: 884 1966;
16 Ratnoff O. D, Busse J. R, Sheon R. P. The demise of John Hageman. New Engl. J. Med 279: 760 1968;
17 Macfarlane R. G. The blood clotting mechanism. Proc. Roy. Soc. Ser. B 173: 261 1969;
18 Seegers W. H. The purification of prothrombin. Rec. Chem. Progr 13: 143 1952;
19 Mammen E. F, Thomas W. R, Seegers W. H. Activation of purified prothrombin to autoprothrombin I or autoprothrombin II (platelet cofactor II) or autoprothrombin II-A. Thrombos. Diathes. haemorrh. (Stuttg.) 05: 218 1960;
20 Ware A. G, Seegers W. H. Two-stage procedure for the quantitative determination of prothrombin concentration. Amer. J. clin. Path 19: 471 1949;
21 Seegers W. H, Smith H. P. Factors which influence the activity of purified thrombin. Amer. J. Physiol 137: 348 1942;
22 Marciniak E, Seegers W. H. Autoprothrombin C: A second enzyme from prothrombin. Canad. J. Biochem. Physiol 40: 597 1962;
23 Alkjaersig N, Abe T, Seegers W. H. Purification and quantitative determination of platelet factor 3. Amer. J. Physiol 181: 304 1955;
24 Seegers W. H, Marciniak E, Kipfer R. K, Yasunaga K. Isolation and some properties of prethrombin and autoprothrombin III. Arch. Biochem 121: 372 1967;
25 Reno R. S, Seegers W. H. Two-stage procedure for the quantitative determination of autoprothrombin III concentration and some applications. Thrombos. Diathes. haemorrh. (Stuttg.) 18: 198 1967;
26 Seegers W. H. Prothrombin. Harvard Univ. Press. Cambridge, Mass. USA: 1962
27 Connor W. E, Hoak J. C, Warner E. D. Plasma free fatty acids, hypercoagulability, and thrombosis. In: Sherry S, Brinkhous K. M, Genton E, Stengle J. M. Thrombosis. 355 Nat. Acad. Sci. 1969
28 Caldwell M. J, von Kaulla K. N, von Kaulla E, Seegers W. H. Procoagulant material from human urine in prothrombin activation. Thrombos. Diathes. haemorrh. (Stuttg.) 09: 53 1963;
29 Seegers W. H, McCoy L, Marciniak E, Murano G. Theory of blood coagulation: Applications in disseminated intravascular coagulation. Thrombos. Diathes. haemorrh (Stuttg.) Suppl. 36: 239 1969;
30 Triantaphyllopoulos D. C, Triantaphyllopoulos E. Antihemophilic factor-like activity of lysed fibrinogen. Life Sci 06: 601 1967;